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Objective. To verify whether markers of metal homeostasis are related to a magnetoencephalographic index representative of
glutamate-mediated excitability of the primary somatosensory cortex. The index is identiﬁed as the source strength of the earliest
component (M20) of the somatosensory magnetic ﬁelds (SEFs) evoked by right median nerve stimulation at wrist. Method. Thirty
healthy right-handed subjects (51 ± 22 years) were enrolled in the study. A source reconstruction algorithm was applied to assess
the amount of synchronously activated neurons subtending the M20 and the following SEF component (M30), which is generated
by two independent contributions of gabaergic and glutamatergic transmission. Serum copper, ceruloplasmin, iron, transferrin,
transferrin saturation, and zinc levels were measured. Results. Total copper and ceruloplasmin negatively correlated with the
M20 source strength. Conclusion. This pilot study suggests that higher level of body copper reserve, as marked by ceruloplasmin
variations, parallels lower cortical glutamatergic responsiveness.
1.Introduction
Inthelastdecade,growingevidencehasunveiledtheinvolve-
ment of speciﬁc metals in brain cortical neurotransmission
and the role played by their disarrangements in neurode-
generation. It is well established, for example, that cognitive
impairments often follow conditions of metal imbalance,
which can be either deﬁciency, as in Menkes’ disease, or
accumulation, as in Wilson’s disease or aceruloplasmine-
mia [1–6]. Recently, it has been demonstrated that metal
dyshomeostases linked to mutations and polymorphisms of
speciﬁc genes, such as ATP7B in Alzheimer’s disease (AD,
[7]), the gene of ceruloplasmin in Parkinsons’ disease (PD,
[8, 9]), the gene of hemochromatosis (HFE) in multiple
sclerosis [10, 11] and in AD [12–14], increase the risk
of developing those diseases. Copper and zinc have been
advocated as primary actors in the neurotransmission of
glutamatergic synapses in brain areas that are critical for
AD [5, 15, 16]. Iron appears instead mostly involved in
dopaminergic neurotransmission [17].
Most of the data on the role of metals in neurotrans-
mission come from studies in vitro or animal models, while
data in humans are still rather scanty. For this reason, in
the current study, we approached the issue in man aiming
at assessing whether systemic concentrations of copper, iron,
and their related proteins are associated with speciﬁc brain
indices of cortical glutamatergic neurotransmission.
Glutamate mediates the excitatory neurotransmission in
brain networks that are key for sensory perception, memory,
and sensorimotor control. In particular, glutamate is the
excitatory neurotransmitter of the thalamocortical inputs
to the primary visual, auditory, and somatosensory cortices2 International Journal of Alzheimer’s Disease
[18, 19], which makes it crucial for the cortical hierarchic
structure controlling the interactions with the environment.
We focused on the primary somatosensory cortex (S1,
[20]), since it receives the incoming stimulus via a simple
circuit (relayed by only two subcortical nuclei in the brain
stem and thalamus) and used a median nerve stimulation
protocol. It is known that the earliest cortical response
to peripheral nerve stimulation, the M20, results from
the glutamate-mediated excitatory postsynaptic potentials
(EPSPs, [21–23] generated by area 3b’s pyramidal neurons
[24–26]. The fact that M20 is highly reliable and is not
aﬀected by the subject attention [27] makes its ECD strength
a good index of glutamate-mediated excitability in clinical
studies, where patient compliance could be limited.
We used MEG to record cerebral activity. Selective
sensitivity to electrical currents directed tangentially to
the scalp [28] and the cytoarchitectonic distribution of
pyramidal cells columns (perpendicular to the cortical
surface) make MEG highly sensitive to the activity of area
3b [29–31]. We used localization algorithms to assess the
amount of synchronously activated neurons independently
of their position. In other words, we wanted the estimate
of glutamate-mediated excitability independent of both the
recording apparatus positioning with respect to the subject
and the individual central sulcus shaping with respect to the
scalp.
The aim of our work was twofold: (1) to assess non-
invasively in healthy people possible relationships between
glutamate-mediated neuronal excitability and metal known
to aﬀect this neurotransmission path. (2) To explicate the
existence of a noninvasive index of S1 glutamate-mediated
excitability (M20 ECD strength), whose reliability will be
indirectly strengthened by the ability to assess such relation-
ships.
2.MaterialsandMethods
The study was conformed with The Code of Ethics expressed
in the Declaration of Helsinki and was approved by the
Ethical Committee of the “San Giovanni Calibita” Fatebene-
fratelli Hospital. All subjects signed an informed consent.
2.1. Subjects. Thirty healthy and drug-free subjects (16
females, mean age 51 ± 22, age range [24–93] years) were
enrolled in the study. All were right handed with a mean
Edinburgh Inventory test score of 83 ± 4[ 32]. Neurological
history and examination were assessed to exclude sensory
deﬁcit. Electroneurographic study of upper extremities was
conducted to exclude subclinical deﬁcit of sensitive ﬁbres.
Twenty-seven out of the 30 recruited had a complete data set
that entered the statistical analysis.
2.2. Biochemical Investigations. Samples of serum from
overnight fasting blood were drawn in the morning and
rapidly stored at −80◦C. Biochemical variables were deter-
mined according to established methods reported in details
elsewhere [33]. Brieﬂy, serum copper concentrations were
measured following the method of Abe et al. [34]( R a n d o x
Laboratories, Crumlin, UK) and by an A Aanalyst 300 Perkin
Elmer atomic absorption spectrophotometer equipped with
a graphite furnace with platform HGA 800. Transferrin [35]
and ceruloplasmin [36] were measured by immunoturbidi-
metric assays (Horiba ABX, Montpellier, France).
Serum iron levels were determined using a Ferene col-
orimetric method (Horiba ABX, Montpellier, France) [37].
TF saturation (%TF-sat) was calculated by dividing serum
iron by the total iron-binding capacity (TBC = TF in mg/dL
∗ 1.25) and multiplying by 100. Zinc level was measured
using the speciﬁc complexant 5-Br-PAPS [(2-5-bromo-2-
pyridylazo)-5-(N-propyl-N-sulfo-propylamino) phenol] ac-
cording to manufacturer instructions (Zinc, Sentinel Diag-
nostic, Milan, Italy) (Figure 1).
All biochemical measures were automated on a Cobas
Mira Plus analyser (Horiba ABX, Montpellier, France) and
performed in duplicate. For each serum copper (total
copper) and ceruloplasmin pair, we computed the amount
of copper bound to ceruloplasmin (CuB) and the amount of
copper not bound to ceruloplasmin (free copper) following
standard procedures [38]; brieﬂy: CuB = ceruloplasmin
(mg/dL) ∗ 10 ∗ n; n = 0.0472 (μmol/mg); free copper =
total copper−CuB). This calculation expresses free copper in
μmol/L and is based on the fact that ceruloplasmin contains
0.3% of copper [38] .T h u s ,f o ras u b j e c twi t has e r u mc o p p e r
concentration of 17.3μmol/L and a serum ceruloplasmin
concentration of 33mg/dL, the bound copper concentration
= 33 ∗ 10 ∗ 0.0472 = 15.6μmol/L, and the free copper
concentration = 17.3−15.6 = 1.7μmol/L.
2.3. MEG Investigation. Brain magnetic ﬁelds were recorded
from the left rolandic region by means of a 28-channel MEG
system[39]coveringascalpareaofabout180cm2,operating
inside a magnetically shielded room (Vacuumschmelze).
Cortical evoked responses were recorded (band-pass ﬁltered
0.48–250Hz, sampling rate 1000Hz) during unilateral
0.2ms long electric pulses (631ms interstimulus interval) of
the right median nerve at wrist, delivered through surface
disks with proximal cathode. Stimulus intensity was adjusted
until inducing a painless thumb twitch. In this way, all
the proprioceptive and the superﬁcial perception ﬁbres
are engaged, and neural recruitment is mainly dependent
on measurable functional/anatomical circuitry. Moreover,
the standardization of stimulus intensity just above motor
threshold has been demonstrated to be able to evidence
interindividual relationships of primary somatosensory
cortical response amplitude with age and gender [40]. The
electrical stimulation was delivered to the dominant right
median nerve and the cerebral activity recoded contra-
laterally.
The MEG signals from each of the 28 channels were
averaged on the galvanic nerve stimulation at wrist (t = 0,
about 300 responses) obtaining the SEFs. The primary
cortical responsiveness was estimated by latency, position,
and strength of the sources activated in correspondence to
the two earliest components (M20 and M30), modelled by
equivalent current dipoles (ECDs) within a homogenously
conducting sphere, and solution accepted only if explained
variance was above 95%.International Journal of Alzheimer’s Disease 3
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Figure 1: MEG primary sensorimotor cortex excitability indexes. Top left: in a representative subject, the superimposition of all left rolandic
regionchannelsinthe[−20,100]msperiod,0beingthemomentofthegalvanicstimulusarrivaltotherightmediannerveatwrist.Topright:
thepositionoftheECDsexplainingthecerebralactivationincorrespondencetotheM20(whitecircle)andM30(blackcircle)componentsis
projectedontoasuitableaxialmagneticresonanceimageslice,throughintegrationonthebasisofindividualanatomicallandmarks.Bottom:
schematic representation of currents subtending M20 and M30 generators in a suitable sagittal section of primary sensory and motor areas.
Orange arrow indicates current induced by EPSP and purple arrow the eﬀect of IPSP. Circles represent the position of the corresponding
equivalent current dipole. The M20 component is mainly generated by EPSPs impinging on pyramidal neurons in area 3b and is mediated
by glutamate neurotransmitters. The currents associated with the IPSPs impinging on pyramidal neurons in 3b area are mediated by GABA
neurotransmitter and are added to the EPSPs onto BA4 pyramidal neurons to give rise to M30 component.
Our main target was the ECD strength, representing the
number of synchronously activated neurons [28], estimated
by the localization algorithm in parallel to the ECD position,
so that the strength estimate is independent of the source
position with respect to the recording apparatus.
2.4. Statistical Analysis. All MEG and biochemical variable
did not diﬀer from a Gaussian distributions (Kolmogorov-
Smirnov test, P>0.200 consistently).
To make the analysis independent of personal data,
correlation with age was checked by computing Pearson
coeﬃcients. Gender dependence of M20 and M30 ECD
strengths was evaluated by a multivariate analysis of vari-
ance with component (M20 and M30) as within-subject
factors and gender (women and man) as between-subject
factor. Independent-sample t-test was used to estimate
the dependence on gender of the biochemical variables.
The association of metal metabolism factors and primary
somatosensory neural excitability was studied by correlation
matrices between biochemical variables and left M20 and
M30 ECD strengths after correction for dependence on age
orgenderwhennecessary.Bonferronicorrectionformultiple
comparisons was applied.
3. Results
We controlled MEG indices and biometal variables for
gender eﬀects, but none was found (between-subject factor
gender P>0.200). Thus, descriptive values are provided
as a whole (Table 1). M20 ECD strength (r = 0.403, P =
0.027), iron (r =− 0.478, P = 0.009), and transferrin (r =
−0.431, P = 0.014) were instead correlated for age. Thus,
age dependence of M20 ECD strengths, iron, and transferrin
levels was considered in all statistical analyses, and partial
correlationswerecomputedtocorrectfortheageeﬀect.Posi-
t i o n so fe i t h e rM 2 0E C Do rM 3 0E C D( Table 2) displayed no
dependence on age or gender. No correlations were found
between the M20 and M30 strengths (P>0.200).4 International Journal of Alzheimer’s Disease
Table 1: Metals/metal-related proteins.
Study panel Reference values
Copper [μmol/L] 13.61 (2.53) 11–24.4
Ceruloplasmin [mg/dL] 26.29 (4.90) 20–60
Free copper [μmol/L] 1.20 (1.96) <1.6
Zinc [μg/dL] 85.32 (14.75) 68–107
Iron [μg/dL] 98.68 (32.92) 37–164
Transferrin [g/L ] 2.76 (0.41) 2–3.6
Transferrin saturation [%] 28.2 (8.4) 12–50%
Mean (standard deviation) of metals and metal-related proteins in serum.
Table 2: M20 and M30 ECD positions and strengths.
x [mm] y [mm] z [mm] s [nA·m]
M20 −42 −13 69 17.6
ECD (10) (11) (13) (9.3)
M30 −38 −12 71 21.5
ECD (9) (9) (10) (16.3)
Mean (standard deviation) position (x, y, and z) and strength (s)o f
left M20 and M30 ECDs. Coordinate system is deﬁned on the basis of
anatomical landmarks so that central axis passes through the midline
between the two hemispheres, the positive y-axis passes through the nasion
and the midpoint between the two preauricular points, and the positive z-
axis passes through the vertex perpendicular to y-axes; thus, the positive x-
axis is rightward.
The assessment of the biological variables under study
indicated that the healthy subjects evaluated in this panel
had values coherent with normal reference ranges reported
in literature (Table 1). Our statistical analyses revealed that
among the biological variables under study, only copper
correlated with M20 ECD strength (Table 3). In particular,
higherlevelsofcoppercorrespondedtolowerM20strengths.
We also examined the relation between MEG indices and
the two main components of serum copper: ceruloplasmin
and free copper (see Section 2). M20 ECD strength did not
correlate with free copper, but it displayed a strong inverse
correlationwithceruloplasmin(Figure 2),similarlytoserum
copper (Table 3). Transferrin levels only showed a trend to
inverse correlation with the sole M20 ECD strength, even
though they did not approach signiﬁcance (Table 3).
4. Discussion
The pilot investigation presented in this paper aimed at
evaluating the involvement of systemic biometal-related
variables in human neurotransmission. We focused on a
speciﬁc brain circuit which connects pyramidal neurons in
the somatosensory cortex with a projection coming from
neurons in thalamus. Our main result is that in healthy
subjects, the strength of M20’s ECD, which we deem to be
a good marker of glutamate-mediated cortical excitability, is
associated with the serum concentrations of ceruloplasmin,
which is a marker of copper status.
Table 3: Correlation between SM1 excitability and metals/metal-
related proteins.
M20 ECD
strength
M30 ECD
strength
Copper
−0.643
(<.0001)
0.185
(.435)
Ceruloplasmin
−0.559
(.003)
0.303
(.194)
Free copper
−0.195
(.340)
−0.131
(.560)
Zinc 0.060
(0.808)
−0.015
(0.952)
Iron
−0.134
(0.522)
−0.002
(0.994)
Transferrin
−0.379
(0.068)
−0.065
(0.786)
Transferrin saturation
−0.23
(0.918)
0.080
(0.746)
Correlations (and statistical signiﬁcance P) between primary sensorimotor
cortex excitability and metals or metal-related proteins in serum. Note
that correlation values are equal for ceruloplasmin-bound copper and
ceruloplasmin (see Section 2). In bold correlation values with P<. 005
(Bonferroni correction for multiple comparisons).
4.1. Higher Copper Levels Associated with Lower Gluta-
matergic Excitability. The inﬂuence of copper on cortical
glutamatergic transmission has been extensively demon-
strated at a synaptic level, as copper has been shown to
act as a high-aﬃnity NMDA receptor blocker in a voltage-
dependent manner [41]. Copper—through the Menkes
adenosine triphosphatase (ATPase)—is directly involved
in both α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPA) and N-methyl-D-aspartic acid
(NMDA) glutamatergic receptors modulation, resulting in
the inhibition of glutamate-mediated neurotransmission
[15, 16, 42, 43]. In diverse methodological settings (rat
olfactory bulb, [44] long-term potentiation (LTP) in rat
hippocampus [45], copper has been demonstrated to be
released from copper-containing vesicles in the synaptic cleft
postsynaptically, after NMDA receptor activation, causing
a depression or a complete blockage of the glutamate-
mediated neurotransmission. ATPase7A, also known as the
Menkes protein, was shown to be crucial for glutamatergic
neurotransmission modulation. This copper chaperone was
deemed to pump and accumulate copper into synaptic
vesicles, replenishing a pool of copper to be released upon
NMDAreceptorstimulation. Copper releasedin thesynaptic
cleft functionally blocks NMDA receptor limiting Ca2+ entry
and depolarization of the postsynaptic element [41, 45–47].
Additional copper proteins, such as mettallothiens-3, CuZn
superoxide dismutase, and cytochrome, have been reported
to modulate glutamatergic synaptic activity and to sustain
neurotransmission.
Finally, a similar mechanism was reported in other types
of synapses, as, for example, those regulated by the P2X
family receptors, which form nonselective channels activated
by extracellular ATP. These receptors are widely expressed
in the CNS and are involved in synaptic plasticity and inInternational Journal of Alzheimer’s Disease 5
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Figure 2: Ceruloplasmin and S1 cortex excitability. Scatter plot of M20 and M30 ECD strengths with respect to individual ceruloplasmin
circulating levels. Regression lines are shown for signiﬁcant (solid line) and nonsigniﬁcant (dashed line) correlations.
long-term potentiation. In particular, P2X4 receptor activity
is inhibited by Cu2+ [48]. On the presynaptic side, prior
protein (PrPc, [49]) is involved in regulating the presynaptic
Cu2+ concentration and synaptic transmission linked to P2X
receptors [50].
4.2. Ceruloplasmin and Copper Body Reserve. In normal
conditions, about 85–95% of serum copper is structurally
bound to ceruloplasmin, whereas the remainder is loosely
bound to and is exchanged among albumin, α2m a c r o g l o b -
ulin, amino acids, peptides, and several micronutrients and
for this reason, is generally referred to as “free” copper
[38, 51]. It is generally assumed that ceruloplasmin and
free copper are more informative about, respectively, copper
bioavailability or copper toxicity than the levels of serum
copper. Ceruloplasmin is considered a reliable marker of
body copperstatussinceanincreaseinhepaticcopperresults
in a sustained increase in serum ceruloplasmin concentra-
tions [51–53]. Conversely, copper deﬁciency results in a
ceruloplasmin serum decrease [53]. However, this notion
does not hold during infancy, when the liver generates
mostly apoceruloplasmin, which is the form of that protein
which fails to incorporate copper during its synthesis in
the liver, and it is rapidly catabolized [53]. On this ground,
ceruloplasmin levels are largely used to monitor the eﬀects
of decoppering treatments, as, for example, in zinc therapy,
or of chelating agents, as in Wilson’s disease, representing
a noninvasive surrogate marker of the body copper reserve
[6, 54]. Free copper has, instead, been advocated as a
superior diagnostic tool to detect copper toxicity, as in
Wilson’s disease, which is the quintessential example of
copper toxicosis or accumulation [38].
4.3. Copper versus Iron: Relationship with Glutamatergic
Excitability. If on the one hand copper status variations
seem to account for the association of ceruloplasmin-MEG
indices, on the other hand iron variations could be also seen
as an explanatory reason of this association. In fact, iron
metabolism cannot be isolated from copper homeostasis,
since there is a crosstalk between copper and iron, repre-
sented speciﬁcally by ceruloplasmin. Ceruloplasmin is a key
enzyme in iron metabolism, which oxidizes Fe2+ to Fe3+,
thus, facilitating the transfer of cell iron to circulating [55].
In this framework, of particular interest is the cytochrome
oxidase [56], which is an iron depending enzyme for
energy production in the respiratory electron transport
chain of mitochondria, which has been advocated as an
endogenous metabolic marker of neuron typology, tightly
coupling neuronal activity to oxidative energy metabolism
[57]. However, the fact that iron, transferrin (corresponding
tothetotaliron-bindingcapacity),andtransferrinsaturation
(corresponding to the total bound iron), which are all
markers normally used for diagnosis of diseases related to
iron metabolism, show no correlation with M20’s ECD
strength speaks in favor of a primary role of copper in the
glutamatergicneurotransmission-ceruloplasminassociation.
4.4. M20 ECD Strength as Marker of S1 Glutamate-Mediated
Excitability. Certainly, deﬁning M20’s ECD strength as a
marker of glutamate-mediated neurotransmission implies a
simpliﬁcation. However, while previous evidence sustaining
this notion was based on historical cyto- and circuit-
architecture [24], more recent data have also been based
on pharmacological manipulations of neuronal activities
[58]. In particular, the administration of the GABAA agonist6 International Journal of Alzheimer’s Disease
lorazepam failed to attenuate the M20 strength [58]. Con-
versely, the strength of M30, which partially relies on GABA
neurotransmission as demonstrated by its marked reduction
upon lorazepam administration [58], did not associate
with markers of copper metabolism in our study. Further
investigations by proper pharmacological modulation of
glutamate-mediate excitability should be performed to
strengthen the concept of M20 ECD strength as noninvasive
markerofthisneurotransmissionsystem.Itisworthnoticing
that copper density was demonstrated in animal models to
behigherinS1thaninallothercorticalareas[59],suggesting
a possible special role of copper in this primary cortical
district. Whether the involvement of copper in glutamate-
mediated neurotransmission found in S1 can be generalized
to other cerebral regions requires devoted investigations.
To better understand the cause-eﬀect nature of the
relationship between glutamate excitability and copper, we
plan to act on two levels: (1) in healthy subjects, collecting
M20 ECD strength values before and after pharmacological
modulationofspeciﬁcneurotransmissionsystems(gabaergic
transmission by diazepam/lorazepam/zolpidem; less clear
how to modulate selectively glutamatrgic transmission, since
topiramate, which inhibits glutamate transmission, seems
to act also enhancing gabaergic transmission at least at the
level of the human motor cortex) and (2) in patients who
suﬀer from an altered copper metabolism, verifying the
modulation of the copper-glutamate relationship.
4.5. Glutamatergic Excitability and Copper Status in Man.
Human studies of copper homeostasis and of changes in the
function of glutamate transporters have been performed in
neurological diseases, whereas there is a lack of data from
healthy subjects. To the best of our knowledge, a single study
used transcranial magnetic stimulation (TMS) to explore
cortical excitability and proton magnetic resonance spec-
troscopy (MRS) to asses metal-related metabolic function in
amyotrophic lateral sclerosis [60, 61].
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